Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis

Tytuł:
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis
Autorzy:
Ru-yu Xia
Xiao-yang Hu
Yu-tong Fei
Merlin Willcox
Ling-zi Wen
Ming-kun Yu
Li-shan Zhang
Meng-yuan Dai
Guang-he Fei
Mike Thomas
Nick Francis
Tom Wilkinson
Michael Moore
Jian-ping Liu
Temat:
COPD
Exacerbation
Shufeng Jiedu
Systematic review
Meta-analysis
Chinese herbal medicine
Other systems of medicine
RZ201-999
Źródło:
BMC Complementary Medicine and Therapies, Vol 20, Iss 1, Pp 1-11 (2020)
Wydawca:
BMC, 2020.
Rok publikacji:
2020
Kolekcja:
LCC:Other systems of medicine
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2662-7671
Relacje:
http://link.springer.com/article/10.1186/s12906-020-02924-5; https://doaj.org/toc/2662-7671
DOI:
10.1186/s12906-020-02924-5
Dostęp URL:
https://doaj.org/article/1e121429ce4d4ecaa1cc7aac0f349b3d  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.1e121429ce4d4ecaa1cc7aac0f349b3d
Czasopismo naukowe
Abstract Background Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for respiratory infectious diseases. This review aims to evaluate effectiveness and safety of SFJD for AECOPD. Methods A systematic review of randomised controlled trials (RCTs) in patients with AECOPD, who received SFJD as a single intervention or as add-on treatment to usual care. PubMed, the Cochrane Library, EMBASE, Scopus, Web of Science and four Chinese databases were searched from inception to April 2019. Two authors screened trials, extracted data, and assessed risk of bias, independently. Meta-analysis was performed using RevMan 5.3 software. We performed subgroup analyses and sensitivity analyses according to the predefined protocol. Quality of evidence was assessed using GRADE. Results Thirteen RCTs (1036 patients, with 936 inpatients) were included, all compared SFJD in combination with usual care (including antibiotics) to usual care alone. The mean age of participants ranged from 52 to 67 years, with approximately 60% male. Due to lack of blinding and other factors, all trials were of high risk of bias. SFJD was associated with a significant reduction in treatment failure, from 20.1 to 8.3% (11 trials; 815 patients; relative risk 0.43, 95% confidence interval [CI] 0.30 to 0.62), and duration of hospital stay (2 trials; 79 patients; mean difference − 4.32 days, 95% CI − 5.89 to − 2.75 days). No significant difference in adverse events was found between SFJD and control groups. Conclusion Low certainty evidence suggests SFJD may bring additional benefit in reducing treatment failure, shorten hospital stay, and improving symptoms. Further large, high quality RCTs are needed to confirm its benefit and safety. Trial registration PROSPERO CRD42019133682 .

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies